Diatranz Otsuka Genetics

Diatranz Otsuka Genetics is a biotechnology company focused on the development of xenotransplantation solutions for Type 1 Diabetes. The company's primary asset is DIABECELL, which consists of encapsulated porcine pancreatic islet cells that are transplanted into patients to regulate blood glucose levels. This encapsulation technology is designed to protect the cells from the host's immune system, potentially eliminating the need for lifelong immunosuppressive drugs. Originally a joint venture between Living Cell Technologies and Otsuka Pharmaceutical Factory, the company became a wholly-owned subsidiary of Otsuka in 2014. Diatranz Otsuka Genetics continues to explore the potential of cell-based therapies to address significant unmet needs in metabolic diseases.